Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Duodenal Cancer. According to GlobalData, Phase I drugs for Duodenal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mobocertinib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mobocertinib overview
Mobocertinib Succinate (Exkivity) is an oral tyrosine kinase inhibitor that acts as antineoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Mobocertinib (TAK-788, AP-32788) is under development for the treatment of sarcoma, biliary tract cancer, cervical cancer, duodenal cancer, pancreatic cancer, bladder/urinary tract cancer, breast cancer, gastric/esophageal cancer, head and neck cancer and liver failure. The drug candidate is a third-generation EGFR inhibitor. It is administered through oral route and acts by targeting tyrosine kinase including EGFR, HER2, HER4 and BLK specific Exon-20 mutations. The drug candidate is a new molecular entity.
The drug candidate was also under development for the treatment of non-small cell lung cancer.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Mobocertinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
